Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nucleobindin-2 short hairpin RNA
- Development stage
- Preclinical
- Lead developer
- China Medical University
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
Nucleobindin-2 short hairpin RNA (shRNA) is an experimental RNA interference (RNAi) agent designed to silence the expression of the NUCB2 gene. Nucleobindin-2 (NUCB2), the precursor to the anorexigenic peptide nesfatin-1, has been identified as a significant driver of tumor progression, migration, and invasion in various malignancies, including renal cell carcinoma (RCC), breast cancer, and prostate cancer. By targeting NUCB2 mRNA for degradation, this shRNA construct inhibits the epithelial-mesenchymal transition (EMT) and reduces the metastatic potential of cancer cells. Research indicates that NUCB2 suppression modulates the AMPK/mTORC1/ZEB1 signaling pathway, leading to the downregulation of EMT-associated molecules such as Slug and Twist. In vivo studies in murine models have demonstrated that NUCB2 shRNA can effectively inhibit tumor nodule formation, highlighting its potential as a targeted therapeutic strategy for metastatic renal cell carcinoma.
- Other names
- nucleobindin-2 shRNAnucleobindin2 shRNAnucleobindin 2 shRNANUCB2 short hairpin RNANUCB-2 short hairpin RNANUCB 2 short hairpin RNA
02
Targets
NUCB2 (Nucleobindin-2)
Beyond the preview
Go deeper on nucleobindin-2 short hairpin RNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nucleobindin-2 short hairpin RNA.